Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Durvalumab (Durvalumab [4], trade name Imfinzi, Chinese trade name Imfinzi) is a fully humanized anti-PD-L1 monoclonal antibody used to treat cancer. The drug was developed by MedImmune, a wholly-owned subsidiary of AstraZeneca. [5] It is a human immunoglobulin G1κ (IgG1κ) monoclonal antibody that blocks PD-L1 and PD-1 (CD279)


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.